Data collection protocol for specialist harm reduction agencies

 

Data collection protocol for specialist harm reduction agencies

EMCDDA / Correlation Project, 56 p.
2008.


This booklet has been complied within Correlation – European Network Social Inclusion & Health. The project aims to improve access to and the improvement of health and social services for marginalised groups and people. Data collection and evaluation are considered as an important measure to improve the knowledge and evidence base in particular for low threshold services.
The booklet describes the development and the field testing of a data collection protocol for harm reduction agencies and presents the final tool, including a manual. You can find additional information and the inventory on www.correlation-net.org.

 

 

 

Working Group :

  • Randi Ervik, Diakonhjemmet University College, Oslo, Norway
  • Jean Long, Health Research Board, Dublin, Ireland
  • Xavier Majo Roca, Department of Health Catalonia
  • Ferenc Marvanykövi, RIDS Budapest, Hungary
  • Jozsef Racz, RIDS Budapest, Hungary
  • Abdalla Toufik, OFDT Paris, France.

Chair :

  • Dagmar Hedrich, EMCDDA, Lisbon, Portugal

Download the pdf file (282 Ko)

Drugs in Europe


2020 EMCDDA European Drug Report

COVID-19
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
Drug markets
What do the latest data tell us about drug production and trafficking trends?

These and other questions are explored in the 2020 European Drug Report, our annual overview of the drug situation in Europe.

  Statistical Bulletin 2020

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.